Close

Sign in
Sign up

Menu

Data Search
Content
Startup Concierge
Newsletters
Get intel

Home
News
Nuclidium in a €84M series B with Kurma Fund, Angelini Ventures, Wellington Partners, Neva SGR, DTCF, Bayern Kapital, Eurazeo, NRW and HighLight Capital

Nuclidium in a €84M series B with Kurma Fund, Angelini Ventures, Wellington Partners, Neva SGR, DTCF, Bayern Kapital, Eurazeo, NRW and HighLight Capital

Biotech Health services Manufacturing Pharma

Switzerland

Germany

France

United Kingdom

Belgium

Italy

Japan

Investments

01 July 2025

Share:

Interested in more dealflow and deeper data sets from Europe? Please consider joining Nordic 9!

Nuclidium (company)

Switzerland

Biotech Health services Manufacturing Pharma

Total investments received (USD): 96.77M

Round value (USD): 96.77M

Round investors: Eurazeo Bayern Kapital Wellington Partners NRW.BANK HighLight Capital Angelini Ventures Neva SGR Kurma Life Science Partners Vives Fund DeepTech & Climate Fonds

Company: Nuclidium

Industry: Biotech Health services Manufacturing Pharma

Related deals

FoRx raises $50 million series A with EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures

Biotech Health services Manufacturing Pharma

Sweden

Switzerland

Netherlands

United States

Investments 08 December 2025

vVARDIS to secure $50 million in an equity financing round led by OrbiMed

Health services Manufacturing

Switzerland

United States

Investments 30 June 2025

Sidebar

Verticals

Financial Services
Food Industry
Education
E-commerce
Health services
Marketplace

Benelux

Belgium
Netherlands

DACH

Austria
Germany
Switzerland

Nordics and Baltics

Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden

Western Europe

France
Ireland
Italy
Portugal
Spain
United Kingdom

About
Contact
Terms of service
Privacy policy

© All rights reserved Nordic 9 2016-2025. Made with in Stockholm

Top